Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer

Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document * Pathologically confirmed limited stage (LS)-SCLC or extensive stage (ES)-SCLC * LS-SCLC - stage I-III (Tany, Nany, M0) that can be safely treated with radiation doses. Excludes T3-4 due to multiple nodules that are too extensive of have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan * ES-SCLC - stage IV (Tany, Nany, M1), or T3-4 due to multiple nodules that are too extensive of have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan * Must be no more than 6 weeks from having received last dose of chemo- and/or radiotherapy for primary tumor to anticipated start of TTField therapy * Partial response to standard of care (chemo- and/or radiotherapy) as judged by treating physicians with no evidence of recurrence as observed by thoracoabdominal computed tomography (CT) within 12 weeks of enrollment * No brain metastases as observed by gadolinium (gd)-magnetic resonance imaging (MRI) within 12 weeks of enrollment * No previous or currently active second malignancy, with exception of non-metastatic prostate cancer, treated stage I breast cancer, skin malignancies * Life expectancy of at \>= 3 months * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60) * Participants must be willing and able to fully comply with the minimum required 18 hours/day of TTField therapy * Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation Exclusion Criteria: * Malignant disease, other than that being treated in this study, with exception of non-metastatic prostate cancer, treated stage I breast cancer, skin malignancies * Implanted pacemaker, defibrillator or deep brain stimulator, or documented clinically significant arrhythmias * Active implanted medical device (e.g. deep brain stimulators, spinal cord stimulators, vagus nerve stimulators, pacemakers, defibrillators, and programmable shunts) * External medical devices (e.g., insulin pumps) are permitted * Skull defect (e.g. missing bone with no replacement) * Shunt * Bullet fragments * Evidence of increased intracranial pressure (midline shift \> 5 mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness) * Sensitivity to conductive hydrogels * Pregnant or lactating women * Underlying serious skin condition on the scalp, which in the opinion of the investigator, would prevent or interfere with TTField therapy * Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of participant safety or study results